MedTrace Logo

Pembrolizumab and Induction Chemotherapy in Locally Advanced HNSCC

NCT05272696 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 86

Last updated 2025-07-01

No results posted yet for this study

Summary

To study induction therapy with Nab-paclitaxel, Cisplatin and Pembrolizumab in patients with Locally Advanced HNSCC.

Conditions

Interventions

DRUG

Nab-paclitaxel, cisplatin and Pembrolizumab combination

Pembrolizumab in combination with Nab-paclitaxel and cisplatin as induction therapy

PROCEDURE

surgery

Patients with PR but the maximum diameter of tumor \> 3cm or SD or PD can receive surgery directly.

RADIATION

Adjuvant Chemoradiotherapy

After surgery, adjuvant Chemoradiotherapy or radiotherapy will be given for patients with high-risk factors.

DRUG

Radical concurrent chemoradiotherapy

Patients with PR and maximum tumor diameter ≤ 3cm or CR evaluated by MDT after 2 courses induction therapy can receive Radical concurrent chemoradiotherapy. Evaluation was performed 3 months after CRT. After MDT discussion, patients with high-risk factors need maintenance treatment.

Sponsors & Collaborators

  • Guangdong Provincial People's Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2026-01-01
Completion
2026-01-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272696 on ClinicalTrials.gov